Foghorn therapeutics provides first quarter 2024 financial and corporate update

Dose escalation in fhd-286 combination trial in aml continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in aml
FHTX Ratings Summary
FHTX Quant Ranking